• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Lee Newcomer Addresses the Differences Between UnitedHealthcare and CMS' Payment Models

Video

Lee Newcomer, MD, MHA, private consultant, discusses the differences between UnitedHealthcare's pilot episodic payment model and CMS models.

Lee Newcomer, MD, MHA, private consultant, discusses the differences between UnitedHealthcare's pilot episodic payment model and CMS models.

Transcript

What are the differences between UnitedHealthcare’s pilot episodic payment model and CMS models?

Well, first and foremost this was a commercial population rather than Medicare. I think that’s critical because we used the drug margins as one of the ways to fund the episode payment. The margins are much smaller in Medicare because of the contractual rates that they pay.

Probably a second key difference is that, that model used a comparison group from the fee-for-service database. So [UnitedHealthcare] had been collecting clinical information on its commercial patients for almost 7 years. That allowed us to match patients in our pilot episode payment to the fee-for-service fairly exactly.

CMS just didn’t have that database yet but to their credit — they’re building it, and they will get there. But, in the first round they had to use a broader adjustment so rather than saying adjuvant breast cancer, it was just breast cancer. That’s an important difference because it does make the comparisons a lot more accurate to have the most accurate comparison database you can find.

How did UnitedHealthcare work with physician partners to utilize the results from the pilot episodic payment model?

Well the data is always fed back to the physician so we would have an annual meeting with them and bring the data back to them. What OCM I think is doing quite well —now that they have their systems worked out – is giving quarterly data back to the physicians so that they can use it to manage their processes. That’s important because timely data makes the chance of doing this successfully a lot better.

Related Videos
Khush Kharidia, MD
Kimberly Westrich, MA, chief strategy officer, National Pharmaceutical Council
Harry Travis, BS Pharm, MBA, president at The Travis Group, LLC
 Brigid Groves, PharmD, MS, vice president, professional affairs, American Pharmacists Association
Chelsea Renfro, PharmD, research and engagement pharmacist, Vanderbilt Specialty Pharmacy
Chicago skyline with words "CHEST 2025 Recap Chicago, Illinois" | Image credit: SeanPavonePhoto - stock.adobe.com
Screenshot of an interview with Kristina Crothers, MD
James Simon, MD – Image credit: AJMC
Brooke Aggarwal, EdD – screenshot by AJMC
JoAnn Pinkerton, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.